Accordingly, studies have been conducted that incorporate several interventions to treat coagulopathy in patients with sepsis, including administration of anticoagulant supplements such as antithrombin [34,35], activated protein C (drotrecogin α) [36], and recombinant thrombomodulin [37]; however, the results were not optimistic. This evidence concerns the gene THBD and Sepsis.